Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Digestive System Diseases

Rare Diseases

Carcinoma

Breast Neoplasms

Melanoma

Carcinoma, Squamous Cell

Head and Neck Neoplasms

Ovarian Neoplasms

Vulvar Neoplasms

Anus Neoplasms

Uterine Cervical Neoplasms

Rectal Neoplasms

Endometrial Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Skin Diseases

Breast Diseases

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Endocrine System Diseases

Gonadal Disorders

Vulvar Diseases

Anus Diseases

Ovarian Cancer

Anal Cancer

Vulvar Cancer

Each patient receive both injections of Technetium99 (standard care) and indocyanine green.

The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.

Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)

Indocyanine green

Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.

Lymphoscintigraphy is performed to identify the sentinel node

Technetium99

The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.

Optonuclear probe

The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.

Quest Camera

MARCHAL FREDERIC, MD, PU-PH

This is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided sentinel lymph node biopsy in patients with cancers and subjected to surgery.

The diagnostic performance and the tolerance of indocyanine green (ICG) to the radio-isotope (Techniciun99) in the detection of sentinel lymph nodes will be assess using an "Optonuclear" probe (EURORAD S.A.) and QUEST camera

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery

The detection rate is defined by the number of patient who at least one sentinel node detected by fluorescence or isotope intra operatively.

Per-operative detection is defined by the identification of at least one sentinel lymph node in the lymphatic drainage area.

The total number of sentinel node detected will be assess by the two techniques

False negative result is defined by number of patients with at least one hot metastatic sentinel lymph node without fluorescent metastatic sentinel lymph node

Percentage of patients with allergic reactions

Pain will be assessed by a numerical scale from 0 (no pain) to 10 (maximum pain)

The total number of sentinel node detected by fluorescence imaging

Institut de Cancérologie de Lorraine

Symptoms and General Pathology

Nervous System Diseases

Pain, Postoperative

Pain

Fecal Incontinence

Carcinoma in Situ

Postoperative Complications

Neurologic Manifestations

functional studies before and after anal laser ablation

high resolution anal manometry

Tamzin Cuming, FRCS

Christine Inwang, MSc

Tamzin Cuming, FRCS, MBBS

Mayura Nathan, FRCS

High-grade squamous intraepithelial lesions (HSIL) and anal cancer are rising in incidence and at highest risk are HIV positive men who have sex with men (MSM). This pilot study assessing anal function and patient-reported outcomes before and after laser ablation of HSIL will add to the evidence that such a therapy is an acceptable and safe treatment to offer in a preventative setting.We will be recruting HIV positive and negative MSM.

High resolution anoscopy with targeted laser ablation is one of the therapies currently employed to treat HSIL of the anus to prevent progression to anal cancer. The functional outcome of this procedure has not previously been formally assessed.

HIV and negative positive MSM in whom HSIL has been detected will form the study population, as HSIL is prevalent in these patients and intervention is felt to be indicated. Functional assessments will be carried out prior to initial treatment and then repeated six months after laser ablation therapy. The structure, function and sensitivity of the anal canal will be evaluated using endoanal ultrasound, high-resolution anal manometry and anal mucosal electrosensitivity measurements respectively. Patient-reported outcomes will be assessed using questionnaires and semi-structured interviews at baseline, 4 weeks and 6 months post-treatment.

Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)

Changes in pressure vailues - resting pressure and maximum squeeze pressure compared to patient's own pre treatment values

Changes in sensitivity as measured against patients own pre treatment perception

Changes in endoanal ultrasound abnormalities compared to pre-treatment findings

Qualitative subjective physical and psychological well-being 4 weeks and 6 months after procedure of laser mucosal ablation of AIN

Patient reported outcomes, particularly with regard to sexual function and bowel function

Barts & The London NHS Trust

Homerton University Hospital NHS Foundation Trust

Infections

Virus Diseases

Papilloma

Warts

Condylomata Acuminata

Penile Neoplasms

Neoplasms, Squamous Cell

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Communicable Diseases

Papillomavirus Infections

DNA Virus Infections

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Genital Neoplasms, Male

Genital Diseases, Male

Penile Diseases

Male Urogenital Diseases

Penile Cancer

All Drugs and Chemicals

Vaccines

The receiver is an immigrant mother born in Eritrea, Somalia, Syria, Afghanistan, Iran or Iraq.

The receiver is a mother born in Sweden whose education does not exceed 3 years of high school.

The receiver is a mother born in Sweden whose education is at least 3 years of high school but no more than high school diploma.

The receiver is a mother born in Sweden whose education is at least some college (undergrad) but does not exceed an undergraduate degree

The receiver is a mother born in Sweden whose education is an undergraduate degree plus at least some graduate education

A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.

Information T1

A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.

Information T2

A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.

Information C

Lisen A. Dahlström, Ph.D.

Counteracting misinformation on childhood vaccines remains a priority for public health in industrialized countries. Previous research showed that misinformation-induced vaccine hesitancy particularly concerns very highly or very lowly educated parents, and, especially in Europe, specific groups of immigrants. Misinformation framing directly targets specific sub-population of parents by exploiting different cognitive biases, and specific concerns based on cultural norms: this project aims at testing the effectiveness of similar framing techniques applied to positive information on the HPV vaccine by conducting a Randomized Controlled Trial in Stockholm, Sweden. It randomizes emotionally and scientifically/statistically framed information addressing the specific concerns reported by previous literature.

In Europe, non-European immigrants display lower vaccination take-up than natives, a higher prevalence of STDs, and lower usage of publicly-funded treatments. Therefore, migrants (and especially women) face worse preventable health issues. Qualitative research suggests that migrants' lower take-up might be due to culturally founded concerns, which are then exploited and targeted by anti-vax information. These are adverse effects on fertility and, in the case of the HPV vaccine, which is administered at a very young age to prevent a sexually-transmissible infection, on reputational concerns related to incentivizing pre-marital sexual activity. Existing literature also investigates parental education as an alternative explanation to vaccines' mistrust, finding mixed evidence which suggests a non-linear relationship between education level and willingness to vaccinate children. In particular, qualitative research highlights that targeted misinformation addresses emotionally charged contents to lowly educated parents, and pseudo-scientific content to highly educated parents.

In this study, 7500 mothers of children (girls and boys) who are due to be offered the HPV vaccine in fall 2021 within the Swedish national vaccination program are randomly sampled. Mothers are stratified according to immigration status, and are sampled from the entire relevant population through Swedish population registers. There are 5 strata: (i) Mothers were born in Iran, Iraq, Afghanistan, Somalia, Eritrea (irrespective of education) (N=2500); (ii) Mothers born in Sweden and have attended at most 3 years of high school (N=1600); (iii) Mothers born in Sweden and have attended more than 3 years of high school and have not attended any university (N=1400); (iv) Mothers born in Sweden and have achieved at most undergraduate education (N=1000); (v) Mothers born in Sweden with graduate education after obtaining an undergraduate degree (N=1000). Sample sizes are chosen with the expectation of having 500 actual participants per stratum, based on participation rate estimates from the implementer (Statistics Sweden, SCB).

Within each stratum, the investigators randomize 3 types of information sheets on the HPV vaccine: emotionally-framed (T1), scientifically and statistically framed (T2) and uninformative placebo (C). Along the information sheet, all mothers receive a first survey covering their beliefs on vaccines (henceforth defined "baseline survey" for simplicity, despite being administered along the treatment), which does not vary across treatment arms. The information sheet and the baseline survey invitation are sent by ordinary post in June 2021 to the mother's address, and the survey can be compiled both on paper and online. In July and August, mothers who have still not compiled the baseline survey will receive 3 reminders: each reminders contains the information sheet, which depending on the specific reminder can be printed or accessible in digital format when accessing the online survey. Between September and October, all mothers will have to decide whether to authorize HPV vaccination for their child, which takes places directly at school and free of charge. In November, mothers who have responded to the baseline survey receive an invitation to an endline survey. All information sheets and surveys are available in Swedish, English, Arabic and Farsi. Informed consent is obtained in the baseline survey. For mothers who choose to participate, investigators will obtain, from population registers, background variables concerning the mother herself, the other parent and the child who is due to immunization. These cover specific information on parents' education, income, wealth and occupation, marital status, number of total children, gender of the child due to HPV vaccination, and if she/he received the previous vaccine in the national program's schedule (3 to 4 years before our intervention), order of the child among siblings.

We are randomly sampling mothers of children who are due for HPV immunization in fall 2021 according to the Swedish national vaccination program. Only for children who do not have a female guardian we invite a male guardian to participate (N=73).

Education, Immigration and HPV Vaccination: an Informational Randomized Trial

Utbildningsnivå, Invandringsstatus Och Viljan Att Vaccinera Mot HPV Som Funktion av Informationsformulering: En Randomiserad Studie

Investigators will assess if there are significant differences in the frequency of parents who decide to vaccinate across treatment arms, within each stratum

The investigators will examine whether across treatment groups, within strata, parents show different degrees of agreement with false statements concerning the risks of HPV, after reading the information sheet corresponding to their treatment arm

The investigators will examine whether across treatment groups, within strata, parents show different degrees of agreement with false statements concerning the risks of HPV, after they have already decided whether to vaccinate their child and vaccination has taken place

Investigators will assess, within strata and across treatment arms, whether individual treatments affected common beliefs about the benefits and risks of the HPV vaccine, which are observed more often among specific group of parents and which are believed to drive vaccine hesitancy. These beliefs are directly addressed by the informational intervention. They concern the perceived benefits/risks of the HPV vaccine relative to fertility, cancer and other illnesses' incidence and sexual behavior, such as whether the HPV vaccine incentivizes sexual activity of teenagers, or if it changes the probability that the teenager develops a cancer in the future. In the second case, the vaccine actually decreases that probability, but anti-vax information would postulate the opposite: we test whether across treatment arms there are significant differences in the degree of agreement with statements on these beliefs.

Investigators will assess whether the treatment effect has a significant interaction with the following variables which, unless specified otherwise, are extracted from population registers based on administrative data: -Field of education (medical vs non-medical and quantitative vs non-quantitative) -Presence of a medical doctor in the close network of the parent\[from baseline survey\] and other parent being a health worker -Self-declared percentage of the information sheet they actually read \[from baseline survey\] -Preferred source of information on vaccines \[from baseline survey\] - Household and mother's wealth - Previous knowledge of HPV and HPV vaccine \[from baseline survey\] -Marital status of the mother - Child being the firstborn - Child being female

Investigators will test, within each stratum, whether the self-reported intention to vaccinate \[post-treatment baseline survey\] and the objective measure of vaccination \[from vaccination registers\] are statistically different. While the objective vaccination indicator is by definition a binary variable, the subjective indicator is initially reported on a Likert scale by subjects, and then reduced to a binary indicator by investigators for immediate comparison.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	NCT02997553	Breast Carcinom... Head and Neck C... Melanoma (Skin) Squamous Cell C... Cervix Cancer Endometrium Can... Ovary Cancer Vulva Cancer Anus Cancer Rectum Cancer	Indocyanine gre... Technetium99 Optonuclear pro... Quest Camera	18 Years -	Institut de Cancérologie de Lorraine
Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)	NCT04109573	Anus Cancer Fecal Incontine... Anal Intraepith... Post Operative ...	high resolution...	18 Years -	Homerton University Hospital NHS Foundation Trust
Education, Immigration and HPV Vaccination: an Informational Randomized Trial	NCT04905030	Cervical Cancer Vulvar Cancer Anus Cancer Penis Cancer Mouse Papilloma Head Cancer Genital Wart Neck Cancer	Information T1 Information T2 Information C	-	Karolinska Institutet
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	NCT02997553	Breast Carcinom... Head and Neck C... Melanoma (Skin) Squamous Cell C... Cervix Cancer Endometrium Can... Ovary Cancer Vulva Cancer Anus Cancer Rectum Cancer	Indocyanine gre... Technetium99 Optonuclear pro... Quest Camera	18 Years -	Institut de Cancérologie de Lorraine

Spots Global Cancer Trial Database for anus cancer

Every month we try and update this database with for anus cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for anus cancer

Every month we try and update this database with for anus cancer cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for anus cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.